PV Bulletin

Plasma Products Lot Release: Notification of Non Compliance

This notification from NPRA indicates cases of non-compliance in plasma product lot releases, necessitating further action.

Primary source: Cancellation of Notified Cosmetic Products

PV Impact Brief

Urgency: HighConfidence: high

What changed

The NPRA has formally notified stakeholders about identified non-compliance issues in the release of plasma product lots, impacting compliance workflows.

Why it matters

Non-compliance in the lot release process can significantly affect product safety, compliance, and market access, thus necessitating immediate corrective action.

Action needed

Entities affected by this notification must review their plasma product lot processes and ensure compliance with NPRA regulations. Affected stakeholders should adjust workflows to address non-compliance issues.

Relevant for
Regulatory Intelligence LeadLabeling Lead
Processes impacted
LabelingCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 16, 2026

Full briefing

Practical implication

Entities affected by this notification must review their plasma product lot processes and ensure compliance with NPRA regulations. Affected stakeholders should adjust workflows to address non-compliance issues.

The National Pharmaceutical Regulatory Agency (NPRA) of Malaysia has issued a notification regarding non-compliance associated with the lot release of plasma products. This formal communication underlines the necessity for stakeholders to adhere to regulatory requirements to ensure public safety.

What changed: The NPRA has formally notified stakeholders about identified non-compliance issues in the release of plasma product lots, impacting compliance workflows.

Why it matters: Non-compliance in the lot release process can significantly affect product safety, compliance, and market access, thus necessitating immediate corrective action.

Practical implication: Entities affected by this notification must review their plasma product lot processes and ensure compliance with NPRA regulations. Affected stakeholders should adjust workflows to address non-compliance issues.

View original source

  • Source: NPRA (Malaysia) - “DRUG REGISTRATION GUIDANCE DOCUMENT
  • Published at source: 2026-08-16T09:18:39.000Z
  • Discovered by monitor: 2026-08-16T09:19:26.059Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Guidance#Malaysia#Source-ingestion#Regulator-monitor#Npra.gov.my

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Urgent Withdrawal of Reusable da Vinci S and Si Instruments Due to Cable Degradation

Urgency: High

Healthcare facilities must isolate the affected instruments and notify Intuitive Surgical for returns while preparing for potential delays in surgical procedures due to instrument replacements.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicANSM · France · Updated Sep 7, 2026Translated From French

Injunction No. 2026-DM-031-INJ Regarding Ortho Partner Establishment in Montreuil

Urgency: High

Establish compliant storage conditions for medical devices and set up a non-conformity management system within 3 months.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward